Enterprise Value
4.933B
Cash
414.1M
Avg Qtr Burn
N/A
Short % of Float
7.49%
Insider Ownership
2.81%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PYLARIFY Details Prostate cancer, Cancer | Approved Quarterly sales | |
RELISTOR Details Constipation | Approved Quarterly sales | |
DEFINITY® Room Temperature Details Suboptimal echocardiograms | Approved Quarterly sales | |
AZEDRA® (iobenguane I 131) Details Pheochromocytoma , Paraganglioma , Solid tumor/s | Approved Quarterly sales | |
¹⁷⁷Lu-PNT2002 Details Cancer, Castration-resistant prostate cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Flurpiridaz F 18 Details Heart disease, Coronary artery disease | Phase 3 Update | |
1095 (PSMA-targeted iodine-131 labeled small molecule) Details Prostate cancer, Glioblastoma, Cancer | Phase 2 Data readout | |
LNTH-1404 Details Prostate cancer, Cancer | Failed Discontinued |